P
US7429379B2ExpiredUtilityPatentIndex 62

TNF receptor action modulation

Assignee: YEDA RES & DEVPriority: May 3, 1992Filed: Apr 14, 2006Granted: Sep 30, 2008
Est. expiryMay 3, 2012(expired)· nominal 20-yr term from priority
Inventors:WALLACH DAVIDBRAKEBUSCH CORD
A61K 38/46C07K 16/2878C07K 14/7151G01N 33/6863A61P 35/00C07K 16/28A61K 38/00
62
PatentIndex Score
3
Cited by
15
References
4
Claims

Abstract

A method of modulating signal transduction and/or cleavage in Tumor Necrosis Factor Receptors (TNF-Rs) is provided. Peptides or other molecules may interact either with the receptor itself, or with effector proteins interacting with the receptor, thus modulating the normal functioning of the TNF-Rs. Such peptides or other molecules may be employed for prophylactic and therapeutic applications in TNF associated diseases.

Claims

exact text as granted — not AI-modified
1. An isolated molecule comprising an antibody or fragment thereof, which antibody or fragment binds to the human p55-TNF-R in the region of amino acids 405-414 of human p55-TNF-R (SEQ ID NO:2). 
     
     
       2. An isolated molecule in accordance with  claim 1 , comprising an antibody that binds to the human p55-TNF-R in the region of amino acids 405-414 of human p55-TNF-R (SEQ ID NO:2). 
     
     
       3. An isolated molecule in accordance with  claim 1 , comprising a fragment of an antibody, which fragment and antibody bind to the human p55-TNF-R in the region of amino acids 405-414 of human p55-TNF-R (SEQ ID NO:2). 
     
     
       4. An isolated molecule in accordance with  claim 1 , consisting of an antibody that binds to the human p55-TNF-R in the region of amino acids 405-414 of human p55-TNF-R (SEQ ID NO:2).

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.